DOCSLIB.ORG

Involvement of C-Fos in the Promotion of Cancer Stem-Like Cell Properties

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Published OnlineFirst December 13, 2016; DOI: 10.1158/1078-0432.CCR-16-2811 Biology of Human Tumors Clinical Cancer Research Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma Naoshad Muhammad1, Sourav Bhattacharya1, Robert Steele1, Nancy Phillips1, and Ratna B. Ray1,2 Abstract Purpose: Head and neck squamous cell carcinoma (HNSCC) is these cells tumorigenic in nude mice. Furthermore, subcutaneous the sixth most common cancer worldwide. Although improve- transplantation of c-Fos–overexpressing Cal27 cells (tumorigen- ments in surgical techniques, chemotherapy and radiation deliv- ic) into immunocompromised mice enhanced tumor growth as ery, and supportive care have improved quality of life for patients compared with parental cells. Mechanistic investigations dem- with HNSCC, regional and distant recurrence remain common. onstrated that c-Fos overexpression enhanced the epithelial– Recent evidence suggests that cancer stem-like cells (CSC) play a mesenchymal transition (EMT) state and expression of CSC significant role in recurrence and chemoresistance. We previously markers (Nanog, c-Myc, Sox2, and Notch1). Ectopic expression observed that c-Fos was highly upregulated in the HNSCC sphere– ofc-FosinHNSCCcellsalsodisplaysincreasedsphereforma- forming cells. Consequences of c-Fos upregulation for the biology tion. We further observed that overexpression of c-Fos increased of HNSCC-CSCs are poorly understood. In this study, we inves- the expression of pERK and cyclin D1 in HNSCC cells. tigated the role of c-Fos in renewal of stemness of HNSCC and Conclusions: Together, our results strongly suggest a novel tumor growth. role of c-Fos as a regulator of EMT and cancer stem cell repro- Experimental Design and Results: We generated stable gramming in HNSCC cells, which may hold potential as a CSC- HNSCC cell lines ectopically expressing the c-Fos gene. Exogenous directed therapeutic approach to improve HNSCC treatment. expression of c-Fos in nontumorigenic MDA1386Tu cells makes Clin Cancer Res; 1–9. Ó2016 AACR. Introduction of c-Jun and ultimately forms the transcription factor–activating protein 1 (AP-1). As a member of AP-1 family, c-Fos protein is Head and neck squamous cell carcinoma (HNSCC) is the sixth associated primarily in signal transduction, cell differentiation, most prevalent cancer in the world. Overall survival rate has not and proliferation (6). However, the downstream signaling path- improved in the past couple of decades, despite significant ways induced by c-Fos activation and their role in tumorigenesis improvements in surgical procedures, radiotherapy, and chemo- and metastasis remains to be understood. therapy. Thus, gaining insights into the signaling pathways that Transgenic mice overexpressing the c-Fos proto-oncogene post- control the high incidence of local recurrence and distant metas- natally develop osteosarcomas with 100% penetrance (7). In tases will be instrumental for developing new therapeutic modal- addition, overexpression of c-Fos has been shown to promote ities for the management of HNSCC. Solid tumors contain a small drug resistance phenotype (8). c-Fos can cause a loss of cell population of cancer stem-like cells (CSC) in several types of polarity and epithelial–mesenchymal transition, leading to inva- cancers including HNSCC, which plays a critical role in the sive and metastatic growth in mammary epithelial cells (9). AP-1 resistance to therapy, facilitating cell growth and metastasis. complex may play a crucial role in the maintenance of colon However, the pathogenesis and biological significance of CSCs cancer stem cells (10). Clinical data suggested that c-Fos may be in HNSCC has not been fully understood. associated with lymph node metastasis in oral cancer (11). Our We have recently observed that c-Fos was upregulated in previous results (1) and these observations in the literature HNSCC-sphere forming cells as compared with parental cells prompted us to investigate the role of c-Fos in cancer stemness (1). c-Fos is a proto-oncogene and present in various types of of HNSCC cells. In this study, we observed that c-Fos expression in cancers including HNSCC (2–5). c-Fos encodes a nuclear DNA- HNSCC cell lines augments cell proliferation, enhances CSC binding protein domain that forms a dimer with the gene product marker gene expression, and promotes tumor growth. Our results strongly demonstrated that c-Fos plays an important role in tumor 1Department of Pathology, Saint Louis University, St. Louis, Missouri. 2Cancer progression and promotes cancer stemness in HNSCC. Center, Saint Louis University, St. Louis, Missouri. Corresponding Author: Ratna B. Ray, Saint Louis University, DRC 207, 1100 Materials and Methods South Grand Boulevard, St. Louis, MO 63104. Phone: 314-977-7822; Fax: 314-771- RNA-seq analysis 3816; E-mail: [email protected] þ À RNA was isolated from CD133 and CD133 cells and RNA- doi: 10.1158/1078-0432.CCR-16-2811 seq was done using Washington University ICTS Core Services. Ó2016 American Association for Cancer Research. Briefly, ribosomal RNA was removed by a hybridization method www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on October 4, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst December 13, 2016; DOI: 10.1158/1078-0432.CCR-16-2811 Muhammad et al. nonreplicating lentiviruswas purchasedfrom Origene.A-Fos(dom- Translational Relevance inant negative) plasmid DNA was obtained from Addgene. Head and neck squamous cell carcinoma (HNSCC) has a high mortality rate despite advancement in chemotherapy, Cell proliferation assay. Cells (Cal27 control, Cal27-c-Fos, radiotherapy, surgical procedure, and targeted therapy. Emerg- MDA1386Tu control, and MDA1386Tu-c-Fos) were seeded in ing evidence implicated that recurrence and metastasis from triplicates, and cells were trypsinized at 24, 48, and 72 hours. All these tumors occur from cancer-like stem cells, although the cells were counted by Trypan blue exclusion method using a mechanism remains unknown. Our study revealed the role of hemocytometer. c-Fos in the promotion of cancer stem-like cell properties in head and neck cancer. Overexpression of c-Fos in nontumori- Sphere (oralspheres) formation assay genic HNSCC cells exhibits tumorigenic phenotype, increases For sphere formation, Cal27 control, Cal27-c-Fos, stemness markers, and increases oralsphere formation. Taken MDA1386Tu control, and MDA1386Tu-c-Fos cells (5,000 cells/ together, our data indicate that c-Fos plays a crucial role in well) were seeded in single-cell suspensions on ultralow attach- driving the stemness properties in HNSCC and may be a good ment plates (Corning) as described previously (1). After 10 days therapeutic target. of incubation, numbers of oralspheres (>75 mm diameter) were counted using inverted microscope (Leica). Western blot analysis and antibodies using Ribo-ZERO kits (EpiCentre). mRNA was then fragmented Cell lysates were analyzed by SDS-PAGE and transferred onto and reverse transcribed to yield double-stranded cDNA. cDNA 0.45 mm nitrocellulose membrane (Bio-Rad). Membranes were was blunt ended, had an A base added to the 3' ends, and then had blocked using 5% low-fat dry milk in TBST and probed with the Illumina sequencing adapters ligated to the ends. Ligated frag- respective primary antibodies. Proteins were detected using ECL ments were then amplified for 12 cycles using primers incorpo- Western Blotting Substrate (Thermo Scientific) and autoradiogra- rating unique index tags. Fragments were sequenced on an Illu- phy. The protein loading was normalized using antibody to mina HiSeq-2500 using single reads extending 50 bases. b-actin or GAPDH. The following antibodies were used in this study: Nanog, Vimentin, c-Met c-Myc, Sox2, Notch 1, pERK, ERK, Cell lines and plasmid DNAs c-Fos (Cell Signaling Technology), cytokeratin19, cyclin D1, and HNSCC cell line (Cal27) were purchased from the ATCC and b-actin (Santa Cruz Biotechnology). nontumorigenic HNSCC MDA1386Tu cells were obtained from Jeff Myers (MD Anderson Cancer Center, Houston, TX), and main- Immunohistochemistry. The paraffin-embedded sections (5-mm tained in gDMEM or RPMI1640 (Sigma) medium supplemented thick) were deparaffinized and stained using antibody against with 10% FBS, and 1% penicillin/streptomycin in a humidified cytokeratin 19 and vimentin, followed by 3,30-diaminobenzidine CO2 incubator. c-Fos-Myc-DDK plasmid DNA or control plasmid staining in clinical histology laboratory. We used mouse mAbs for DNA in mammalian expression vector (Origene) was transfected Cytokeratin 19 (A53-B/A2.26) from Cell Marque (CA) and into Cal27 and MDA1386Tu cell lines, selected with puromycin, Vimentin (V9) from Ventana (AR). The slides were evaluated by pooled for establishment of a stable cell line. c-Fos shRNA in a pathologist (N. Phillips). Table 1. Differentially expressed genes Gene ID Symbol Fold change P FDR Highly upregulated genes 125740 FOSB 382.842 2.99EÀ85 1.73EÀ80 118503 TNFAIP3 195.041 252EÀ44 5.83EÀ40 169429 CXCL8 178.842 8.67EÀ41 1.67EÀ36 114315 HES1 168.761 1.38EÀ38 2.28EÀ34 128422 KRT17 157.761 3.49EÀ36 5.04EÀ32 143537 ADAM15 141.341 1.35EÀ32 1.74EÀ28 143398 PIP5K1A 126.338 2.59EÀ29 2.99EÀ25 137497 NUMA1 104.068 1.95EÀ24 1.88EÀ24 118515 SGK1 102.12 5.23EÀ24 4.64EÀ20 124788 ATXN1 99.408 2.05EÀ23 1.69EÀ19 Highly downregulated genes 150779 TIMM8B 11.899 5.62EÀ04 5.00EÀ02 168036 CTNNB1 11.911 5.58EÀ04 4.97EÀ02 176095 IP6K1 12.046 5.19EÀ04 4.72EÀ02 8710 PKD1 12.358 4.39EÀ04 4.15EÀ02 146678 IGFBP1 13.156 2.87EÀ04 3.00EÀ02 143514 TP53BP2 13.509 2.37EÀ04 2.62EÀ02 198001 IRAK4 14.154 1.68EÀ04 2.04EÀ02 99875 MKNK2 14.175 1.67EÀ04 2.02EÀ02 184545 DUSP8 15.185 9.75EÀ05 1.41EÀ02 33327 GAB2 15.261 9.37EÀ05 1.39EÀ02 OF2 Clin Cancer Res; 2017 Clinical Cancer Research Downloaded from clincancerres.aacrjournals.org on October 4, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst December 13, 2016; DOI: 10.1158/1078-0432.CCR-16-2811 c-Fos in the Enhancement of Cancer Stem-like Properties Figure 1.
Recommended publications
  • RNA-Binding Protein Hnrnpll Regulates Mrna Splicing and Stability During B-Cell to Plasma-Cell Differentiation

    RNA-Binding Protein Hnrnpll Regulates Mrna Splicing and Stability During B-Cell to Plasma-Cell Differentiation

    RNA-binding protein hnRNPLL regulates mRNA splicing and stability during B-cell to plasma-cell differentiation Xing Changa,b, Bin Lic, and Anjana Raoa,b,d,e,1 Divisions of aSignaling and Gene Expression and cVaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; bSanford Consortium for Regenerative Medicine, La Jolla, CA 92037; and dDepartment of Pharmacology and eMoores Cancer Center, University of California at San Diego, La Jolla, CA 92093 Contributed by Anjana Rao, December 2, 2014 (sent for review July 20, 2014) Posttranscriptional regulation is a major mechanism to rewire the RBP-binding sites, thus validating the specificity of RBP binding transcriptomes during differentiation. Heterogeneous nuclear to coprecipitating RNAs and mapping RBP-binding sites on the RNA-binding protein LL (hnRNPLL) is specifically induced in terminally validated RNAs at close to single-nucleotide resolution (8). differentiated lymphocytes, including effector T cells and plasma Heterogeneous nuclear RNA-binding proteins (hnRNPs) is cells. To study the molecular functions of hnRNPLL at a genome- the term applied to a collection of unrelated nuclear RBPs. wide level, we identified hnRNPLL RNA targets and binding sites in hnRNPLL was identified through a targeted lentiviral shRNA plasma cells through integrated Photoactivatable-Ribonucleoside- screen for regulators of CD45RA to CD45RO switching during Enhanced Cross-Linking and Immunoprecipitation (PAR-CLIP) and memory T-cell development (9) and independently through RNA sequencing. hnRNPLL preferentially recognizes CA dinucleo- two separate screens performed by different groups for exclusion tide-containing sequences in introns and 3′ untranslated regions of CD45 exon 4 in a minigene context (10) and for altered CD44 (UTRs), promotes exon inclusion or exclusion in a context-dependent and CD45R expression on T cells in N-ethyl-N-nitrosourea manner, and stabilizes mRNA when associated with 3′ UTRs.
  • TGF-Β1 Signaling Targets Metastasis-Associated Protein 1, a New Effector in Epithelial Cells

    TGF-Β1 Signaling Targets Metastasis-Associated Protein 1, a New Effector in Epithelial Cells

    Oncogene (2011) 30, 2230–2241 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE TGF-b1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells SB Pakala1, K Singh1,3, SDN Reddy1, K Ohshiro1, D-Q Li1, L Mishra2 and R Kumar1 1Department of Biochemistry and Molecular Biology and Institute of Coregulator Biology, The George Washington University Medical Center, Washington, DC, USA and 2Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA In spite of a large number of transforming growth factor b1 gene chromatin in response to upstream signals. The (TGF-b1)-regulated genes, the nature of its targets with TGF-b1-signaling is largely mediated by Smad proteins roles in transformation continues to be poorly understood. (Massague et al., 2005) where Smad2 and Smad3 are Here, we discovered that TGF-b1 stimulates transcription phosphorylated by TGF-b1-receptors and associate with of metastasis-associated protein 1 (MTA1), a dual master the common mediator Smad4, which translocates to the coregulator, in epithelial cells, and that MTA1 status is a nucleus to participate in the expression of TGF-b1-target determinant of TGF-b1-induced epithelial-to-mesenchymal genes (Deckers et al., 2006). Previous studies have shown transition (EMT) phenotypes. In addition, we found that that CUTL1, also known as CDP (CCAAT displacement MTA1/polymerase II/activator protein-1 (AP-1) co-activator protein), a target of TGF-b1, is needed for its short-term complex interacts with the FosB-gene chromatin and stimu- effects of TGF-b1 on cell motility involving Smad4- lates its transcription, and FosB in turn, utilizes FosB/histone dependent pathway (Michl et al.,2005).
  • Wild-Type P53 Can Down-Modulate the Activity of Various Promoters

    Wild-Type P53 Can Down-Modulate the Activity of Various Promoters

    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 9979-9983, November 1991 Biochemistry Wild-type p53 can down-modulate the activity of various promoters DORON GINSBERG*, FATIMA MECHTAt, MOSHE YANIVt, AND MOSHE OREN*t *Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel; and tDepartment of Biotechnology, Pasteur Institute, 75724 Paris Cedex 15, France Communicated by Robert A. Weinberg, August 16, 1991 ABSTRACT The wild-type (wt) p53 protein is the product out whether it could also modulate c-fos expression. We of a tumor suppressor gene that is a frequent target for report here that wt p53 can inhibit c-fos gene expression. This inactivation in many types of tumors. The nuclear localization effect of wt p53 is rapid, suggesting that it may precede ofthe protein, as well as additional features, suggest that it may growth arrest. In addition, cotransfection experiments indi- be involved in the regulation ofgene expression. To explore this cate that wt p53 can down-modulate the activity of a number possibility, the effects of overproduced wt p53 were investi- of promoters. While the effect of wt p53 appeared to be gated in a number of systems. Induction of growth arrest via relatively nonspecific, it probably did not reflect a general- the antiproliferative effect ofwt p53 greatly impaired the ability ized transcriptional shut-off. Our findings suggest that wt p53 of cells to exhibit an increase in c-fos mRNA upon serum may contribute to growth inhibition by down-modulating, stimulation. Experiments in which cells were cotransfected directly or indirectly, the expression of genes that are re- with p53 expression plasmids together with a reporter gene quired for ongoing cell proliferation.
  • Amplitude Modulation of Androgen Signaling by C-MYC

    Amplitude Modulation of Androgen Signaling by C-MYC

    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Amplitude modulation of androgen signaling by c-MYC Min Ni,1,2 Yiwen Chen,3,4 Teng Fei,1,2 Dan Li,1,2 Elgene Lim,1,2 X. Shirley Liu,3,4,5 and Myles Brown1,2,5 1Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 4Harvard School of Public Health, Boston, Massachusetts 02215, USA Androgen-stimulated growth of the molecular apocrine breast cancer subtype is mediated by an androgen receptor (AR)-regulated transcriptional program. However, the molecular details of this AR-centered regulatory network and the roles of other transcription factors that cooperate with AR in the network remain elusive. Here we report a positive feed-forward loop that enhances breast cancer growth involving AR, AR coregulators, and downstream target genes. In the absence of an androgen signal, TCF7L2 interacts with FOXA1 at AR-binding sites and represses the basal expression of AR target genes, including MYC. Direct AR regulation of MYC cooperates with AR-mediated activation of HER2/HER3 signaling. HER2/HER3 signaling increases the transcriptional activity of MYC through phosphorylation of MAD1, leading to increased levels of MYC/MAX heterodimers. MYC in turn reinforces the transcriptional activation of androgen-responsive genes. These results reveal a novel regulatory network in molecular apocrine breast cancers regulated by androgen and AR in which MYC plays a central role as both a key target and a cooperating transcription factor to drive oncogenic growth.
  • Original Article Regulation of Exogenous P53 Combined with Dickkopf-1 on Human Osteosarcoma MG-63 Cells

    Original Article Regulation of Exogenous P53 Combined with Dickkopf-1 on Human Osteosarcoma MG-63 Cells

    Int J Clin Exp Med 2017;10(6):9252-9258 www.ijcem.com /ISSN:1940-5901/IJCEM0052476 Original Article Regulation of exogenous P53 combined with Dickkopf-1 on human osteosarcoma MG-63 cells Fuyu Gao, Benjun Bi, Guangjun Liao Department of Orthopedic Surgery, Yantaishan Hospital, Yantai, Shandong, China Received March 8, 2017; Accepted April 22, 2017; Epub June 15, 2017; Published June 30, 2017 Abstract: Objective: To regulate the growth of human osteosarcoma cell strain MG-63 in vitro through the combined drugs of exogenous P53 gene and Dickkopf-1 and to explore its possible mechanisms in order to provide the refer- ence for clinical treatment of osteosarcoma. Methods: Human osteosarcoma MG-63 cell strain was subcultured in vitro, and exogenous P53 and Dickkopf-1 were used separately or jointly to act on MG-63 cells. The proliferation and apoptosis of MG-63 cells were respectively detected by trypan blue exclusion and flow cytometry; the expres- sion levels of tumor suppressor gene P53 and oncogene c-fos and c-myc were detected by real-time fluorescent quantitative and western blot in mRNA and protein levels. Results: The proliferation test results showed that the combination of exogenous P53 and Dickkopf-1 could significantly inhibit the growth of MG-63 cells, compared with the single drug using (P<0.05), and cell cycle assay found that the combined drugs caused the cell cycle arrest at G0/G1 phase (P<0.05). Flow cytometry assay indicated the apoptosis of MG-63 cells caused by the combined drugs was significantly higher than that of using exogenous P53 or Dickkopf-1 alone, and the results of western blot manifested the combined drugs could down-regulate the expression levels of c-fos and c-myc whichwere related to the proliferation and differentiation of MG-63 cells, and increase the expression of tumor suppressor gene P53.
  • KLF6 Depletion Promotes NF-Κb Signaling in Glioblastoma

    KLF6 Depletion Promotes NF-Κb Signaling in Glioblastoma

    OPEN Oncogene (2017) 36, 3562–3575 www.nature.com/onc ORIGINAL ARTICLE KLF6 depletion promotes NF-κB signaling in glioblastoma AP Masilamani1,2, R Ferrarese1,2, E Kling1,2, NK Thudi3, H Kim4, DM Scholtens5, F Dai1,2, M Hadler1,2, T Unterkircher1,2, L Platania1,2, A Weyerbrock1,2, M Prinz6,7, GY Gillespie8, GR Harsh IV9, M Bredel3,10 and MS Carro1,2,10 Dysregulation of the NF-κB transcription factor occurs in many cancer types. Krüppel-like family of transcription factors (KLFs) regulate the expression of genes involved in cell proliferation, differentiation and survival. Here, we report a new mechanism of NF- κB activation in glioblastoma through depletion of the KLF6 tumor suppressor. We show that KLF6 transactivates multiple genes negatively controlling the NF-κB pathway and consequently reduces NF-κB nuclear localization and downregulates NF-κB targets. Reconstitution of KLF6 attenuates their malignant phenotype and induces neural-like differentiation and senescence, consistent with NF-κB pathway inhibition. KLF6 is heterozygously deleted in 74.5% of the analyzed glioblastomas and predicts unfavorable patient prognosis suggesting that haploinsufficiency is a clinically relevant means of evading KLF6-dependent regulation of NF-κB. Together, our study identifies a new mechanism by which KLF6 regulates NF-κB signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss. Oncogene (2017) 36, 3562–3575; doi:10.1038/onc.2016.507; published online 6 February 2017 INTRODUCTION coding region have been controversial.16,18–22 KLF6 has been The NF-κB transcription factor family is oncogenic through proposed to perform its tumor suppression function by promoting suppression of programmed cell death, and promotion of tumor G1 cell cycle arrest mainly through cyclin-dependent kinase 15 growth and invasion.1 In tumors, NF-κB can be activated by inhibitor 1A (CDKN1A) promoter transactivation.
  • Carcinogeninduced Hepatic Tumors in KLF6+/ Mice Recapitulate

    Carcinogeninduced Hepatic Tumors in KLF6+/ Mice Recapitulate

    HEPATOBILIARY MALIGNANCIES Carcinogen-Induced Hepatic Tumors in KLF61/2 Mice Recapitulate Aggressive Human Hepatocellular Carcinoma Associated with p53 Pathway Deregulation Mirko Tarocchi,1,2 Rebekka Hannivoort,1,3 Yujin Hoshida,4 Ursula E. Lee,1 Diana Vetter,1 Goutham Narla,5,6 Augusto Villanueva,7,8 Moshe Oren,8 Josep M. Llovet,1,7,9 and Scott L. Friedman1 Inactivation of KLF6 is common in hepatocellular carcinoma (HCC) associated with hepa- titis C virus (HCV) infection, thereby abrogating its normal antiproliferative activity in liver cells. The aim of the study was to evaluate the impact of KLF6 depletion on human HCC and experimental hepatocarcinogenesis in vivo. In patients with surgically resected HCC, reduced tumor expression of KLF6 was associated with decreased survival. Consistent with its role as a tumor suppressor, KLF61/2 mice developed significantly more tumors in response to the chemical carcinogen diethyl nitrosamine (DEN) than wild-type animals. Gene expression signatures in both surrounding tissue and tumors of KLF61/2 mice closely recapitulated those associated with aggressive human HCCs. Expression microarray profiling also revealed an increase in Mdm2 mRNA in tumors from KLF61/2 compared with KLF61/1 mice, which was validated by way of quantitative real-time polymerase chain reaction and western blot analysis in both human HCC and DEN-induced murine tumors. Moreover, chromatin immunoprecipitation and cotransfection assays established the P2 intronic promoter of Mdm2 as a bona fide transcriptional target repressed by KLF6. Whereas KLF6 overexpression in HCC cell lines and primary hepatocytes led to reduced MDM2 levels and increased p53 protein and transcriptional activity, reduction in KLF6 by small interfering RNA led to increased MDM2 and reduced p53.
  • Teacher Background on P53 Tumor Suppressor Protein

    Teacher Background on P53 Tumor Suppressor Protein

    Cancer Lab p53 – Teacher Background on p53 Tumor Suppressor Protein Note: The Teacher Background Section is meant to provide information for the teacher about the topic and is tied very closely to the PowerPoint slide show. For greater understanding, the teacher may want to play the slide show as he/she reads the background section. For the students, the slide show can be used in its entirety or can be edited as necessary for a given class. What Is p53 and Where Is the Gene Located? While commonly known as p53, the official name of this gene is Tumor Protein p53 and its official symbol is TP53. TheTP53 gene codes for the TP53 (p53) protein which acts as a tumor suppressor and works in response to DNA damage to orchestrate the repair of damaged DNA. If the DNA cannot be repaired, the p53 protein prevents the cell from dividing and signals it to undergo apoptosis (programmed cell death). The name p53 is due to protein’s 53 kilo-Dalton molecular mass. The gene which codes for this protein is located on the short (p) arm of chromosome 17 at position 13.1 (17p13.1). The gene begins at base pair 7,571,719 and ends at base pair 7, 590,862 making it 19,143 base pairs long. (1, 2) What Does the p53 Gene Look Like When Translated Into Protein? The TP53 gene has 11 exons and a very large 10 kb intron between exons 1 and 2. In humans, exon 1 is non-coding and it has been shown that this region could form a stable stem-loop structure which binds tightly to normal p53 but not to mutant p53 proteins.
  • KLF6-SV1 Overexpression Accelerates Human and Mouse Prostate Cancer Progression and Metastasis

    KLF6-SV1 Overexpression Accelerates Human and Mouse Prostate Cancer Progression and Metastasis

    KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis Goutham Narla, … , Mark A. Rubin, John A. Martignetti J Clin Invest. 2008;118(8):2711-2721. https://doi.org/10.1172/JCI34780. Research Article Oncology Metastatic prostate cancer (PCa) is one of the leading causes of death from cancer in men. The molecular mechanisms underlying the transition from localized tumor to hormone-refractory metastatic PCa remain largely unknown, and their identification is key for predicting prognosis and targeted therapy. Here we demonstrated that increased expression of a splice variant of the Kruppel-like factor 6 (KLF6) tumor suppressor gene, known as KLF6-SV1, in tumors from men after prostatectomy predicted markedly poorer survival and disease recurrence profiles. Analysis of tumor samples revealed that KLF6-SV1 levels were specifically upregulated in hormone-refractory metastatic PCa. In 2 complementary mouse models of metastatic PCa, KLF6-SV1–overexpressing PCa cells were shown by in vivo and ex vivo bioluminescent imaging to metastasize more rapidly and to disseminate to lymph nodes, bone, and brain more often. Interestingly, while KLF6-SV1 overexpression increased metastasis, it did not affect localized tumor growth. KLF6-SV1 inhibition using RNAi induced spontaneous apoptosis in cultured PCa cell lines and suppressed tumor growth in mice. Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target. Find the latest version: https://jci.me/34780/pdf Research article KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis Goutham Narla,1,2 Analisa DiFeo,1 Yolanda Fernandez,1 Saravana Dhanasekaran,3 Fei Huang,1 Jaya Sangodkar,1,2 Eldad Hod,2 Devin Leake,4 Scott L.
  • Cross-Family Dimerization of Transcription Factors Fos/Jun

    Cross-Family Dimerization of Transcription Factors Fos/Jun

    Proc. Nati. Acad. Sci. USA Vol. 88, pp. 3720-3724, May 9, 1991 Biochemistry Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity (gene regulation/oncogenes/leucine zipper/protein dimerization/transcription) TSONWIN HAI*t AND ToM CURRANt of Medical Biochemistry and Ohio State Biotechnology Center, Ohio State University, 1060 Carmack Road, Columbus, OH 43210; and tDepartment*Department of Molecular Oncology and Virology, Roche Institute of Molecular Biology, Roche Research Center, Nutley, NJ 07110 Communicated by Herbert Weissbach, January 31, 1991 ABSTRACT The Fos/Jun and ATF/CREB families of Table 1. Mammalian Fos/Jun and ATF/CREB families transcription factors function in coupling extracellular signals Family Subfamily Gene(s) to alterations in expression of specific target genes. Like many eukaryotic transcription factors, these proteins bind to DNA as Fos/Jun Fos fos, fra-), fra-2, fosB dimers. Dimerization is mediated by a structure known as the Jun c-jun, junB, junD "leucine-zipper" motif. Although Fos/Jun and ATF/CREB ATF/CREB CREB CREB, ATF-I were previously thought to interact preferentially with differ- CRE-BP1 CRE-BPI, ATF-a ent DNA regulatory elements (the AP-1/TRE and ATF/CRE ATF-3 ATF-3* sites, respectively), we rind that members of these two families ATF-4 ATF4* form selective cross-family heterodimers. The resulting het- Alternative names for CRE-BPI are ATF-2 and HB16. ACREB is erodimers display distinguishable DNA binding speclfcities a spliced variant ofCREB, ATF-aA is a spliced variant ofATF-a, and from each other and from their parental homodimers.
  • Jdp2 Downregulates Trp53 Transcription to Promote Leukaemogenesis in the Context of Trp53 Heterozygosity

    Jdp2 Downregulates Trp53 Transcription to Promote Leukaemogenesis in the Context of Trp53 Heterozygosity

    Oncogene (2013) 32, 397 --402 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc SHORT COMMUNICATION Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity L van der Weyden1, AG Rust1,4, RE McIntyre1,4, CD Robles-Espinoza1, M del Castillo Velasco-Herrera1, R Strogantsev2, AC Ferguson-Smith2, S McCarthy1, TM Keane1, MJ Arends3 and DJ Adams1 We performed a genetic screen in mice to identify candidate genes that are associated with leukaemogenesis in the context of Trp53 heterozygosity. To do this we generated Trp53 heterozygous mice carrying the T2/Onc transposon and SB11 transposase alleles to allow transposon-mediated insertional mutagenesis to occur. From the resulting leukaemias/lymphomas that developed in these mice, we identified nine loci that are potentially associated with tumour formation in the context of Trp53 heterozygosity, including AB041803 and the Jun dimerization protein 2 (Jdp2). We show that Jdp2 transcriptionally regulates the Trp53 promoter, via an atypical AP-1 site, and that Jdp2 expression negatively regulates Trp53 expression levels. This study is the first to identify a genetic mechanism for tumour formation in the context of Trp53 heterozygosity. Oncogene (2013) 32, 397--402; doi:10.1038/onc.2012.56; published online 27 February 2012 Keywords: p53; Jdp2; transposon; heterozygosity; lymphoma; mice INTRODUCTION targeted by transposon insertion events leading to upregulated Genetic alterations of TP53 are frequent events in tumourigenesis Jdp2 expression and a decrease in Trp53 expression levels. Further and promote genomic instability, impair apoptosis, and contribute we illustrate that Jdp2 regulates the Trp53 promoter via an atypical to aberrant self-renewal.1--4 The spectrum of mutations that occur AP-1 binding site.
  • RB1 and P53 at the Crossroad of EMT and Triple Negative Breast Cancer

    RB1 and P53 at the Crossroad of EMT and Triple Negative Breast Cancer

    PERSPECTIVE PERSPECTIVE Cell Cycle 10:10, 1-8; May 15, 2011; © 2011 Landes Bioscience RB1 and p53 at the crossroad of EMT and triple negative breast cancer Zhe Jiang,1 Robert Jones,1 Jeff C. Liu,1 Tao Deng,1 Tyler Robinson,1 Philip E.D. Chung,1 Sharon Wang,1 Jason I. Herschkowitz,2 Sean E. Egan,3 Charles M. Perou4 and Eldad Zacksenhaus1,* 1Division of Cell and Molecular Biology; Toronto General Research Institute; University Health Network; Toronto, Ontario, Canada; 2Department of Molecular and Cellular Biology; Baylor College of Medicine; Houston, TX USA; 3Program in Developmental and Stem Cell Biology; The Hospital for Sick Children; Department of Molecular Genetics; University of Toronto; Toronto, Ontario, Canada; 4Lineberger Comprehensive Cancer Center; Department of Genetics and Pathology; University of North Carolina at Chapel Hill; Chapel Hill, NC USA riple negative breast cancer (TNBC) NEU-positive and Triple Negative (TN) Tis a heterogeneous disease that tumors, the latter of which do not express includes Basal-like and Claudin-low hormone receptors or HER2.1-7 TNBC tumors. The Claudin-low tumors are affects 15–30% of patients. By IHC it can enriched for features associated with be further divided into Basal-like breast epithelial-to-mesenchymal transition cancer and non-basal tumors, some of (EMT) and possibly for tumor initiating which exhibit features of EMT.8 Basal-like cells. Primary TNBCs respond relatively BCs express the basal cytokeratins (CK) well to conventional chemotherapy; CK5/6, CK14, CK17, and/or epidermal © 2011 Landes Bioscience. Landes ©2011 however, metastatic disease is virtually growth factor receptor (EGFR), whereas incurable.